DexCom, Inc.

69.23-1.40 (-1.98%)

Oct 28, 4:00:02 PM EDT · NasdaqGS · DXCM · USD

Upcoming Earnings

Report date

Oct 30, 2025 (tomorrow)

Key Stats

Market Cap

27.15B

P/E (TTM)

48.75

Basic EPS (TTM)

1.42

Dividend Yield

Recent Filings

8-K

10/27/25Oct 27, 2025

8-K

CEO takes medical leave

9/16/25Sep 16, 2025

Dexcom's CEO Kevin Sayer stepped into a temporary medical leave on September 14, 2025, prompting the board to name COO Jacob Leach as interim CEO while he keeps his current role. Lead Independent Director Mark Foletta took over as interim chairman. Neither will pocket extra pay for these gigs. Leadership continuity holds firm amid the shift.

8-K

Dexcom Q2 beats, CEO shift

7/30/25Jul 30, 2025

Dexcom reported Q2 2025 revenue of $1.157 billion, up 15% year-over-year, with GAAP operating income rising to $212.6 million from $158.0 million, fueled by U.S. and international growth. The company secured FDA clearance for its G7 15 Day CGM System and raised full-year revenue guidance to $4.600-$4.625 billion. Leadership transitions on January 1, 2026, see Kevin Sayer retire as CEO to become Executive Chairman while Jacob Leach steps up from President and COO. Smooth handover ahead.

10-Q

Q2 FY2025 results

7/30/25Jul 30, 2025

Dexcom's Q2 revenue climbed 15% year-over-year to $1.16 billion, fueled by sensor sales volume amid a growing customer base, while gross margin dipped to 59.5% from 62.4% due to supply inefficiencies and mix shifts. Operating income rose 35% to $212.6 million, with diluted EPS up 29% to $0.45 on 408.2 million shares; YTD figures align consistently at $0.71 per share. Cash from operations hit $486.8 million YTD, free cash flow $305.7 million (derived), bolstering $2.93 billion in cash and equivalents against $2.45 billion in convertible notes due 2025 and 2028. No M&A noted. Revenue thrives on U.S. dominance at 73%. Yet regulatory scrutiny lingers from the FDA's March 2025 warning letter on quality systems.

8-K

Leach promoted to President and COO

5/13/25May 13, 2025

DexCom promoted Jacob S. Leach to President and Chief Operating Officer on May 9, 2025, expanding his role to include corporate development and strategy while retaining oversight of product development, global operations, and R&D. With 21 years at the company, Leach's base salary rises to $800,000, plus a 100% target performance bonus. This bolsters leadership for innovation in glucose biosensing. Confidence in Dexcom's future runs high.

About

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for the management of diabetes and metabolic health by patients, caregivers, and clinicians. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions; and Stelo, a new over-the-counter glucose biosensor designed for adults with prediabetes and Type 2 diabetes. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.

CEO

Mr. Jacob Steven Leach

IPO

4/14/2005

Website

https://www.dexcom.com/global

Employees

10,200

Sector

Healthcare

Industry

Medical Devices